Management of immune checkpoint inhibitor‐related rheumatic adverse events

Management of immune checkpoint inhibitor‐related rheumatic adverse events

Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...

Full description

Bibliographic Details
Main Authors: Jiaxin Zhou, Hanping Wang, Xiaoxiao Guo, Qian Wang, Lian Duan, Xiaoyan Si, Li Zhang, Xiaowei Liu, Yue Li, Wen Zhang
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Thoracic Cancer
Subjects:
Immune checkpoint inhibitors
immune‐related adverse events
rheumatic disease
treatment
Online Access:https://doi.org/10.1111/1759-7714.13249

Internet

https://doi.org/10.1111/1759-7714.13249

Similar Items